Skip to main content
SpringerLink
Log in
Book cover

Neuroimaging of Movement Disorders pp 129–141Cite as

Dopamine Imaging in Idiopathic Parkinson Disease and Other Parkinsonisms

  • Chapter
  • First Online:

Part of the book series: Current Clinical Neurology ((CCNEU,volume 44))

Abstract

Parkinsonism is clinically characterised by slowed movement, muscle rigidity, tremor at rest and postural instability, along with a variety of non-motor features. Many of these findings are closely linked to the progressive loss of nigrostriatal dopamine neurons. Various methods have been developed to image dopamine in the brain. This chapter will review the various imaging methods and summarise the diagnostic utility of dopamine imaging in idiopathic Parkinson disease (iPD) and other related disorders. Discussion will also provide insights into future applications of dopamine imaging, including its use as a biomarker in clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.

    Article  PubMed  Google Scholar 

  2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–55.

    Article  PubMed  CAS  Google Scholar 

  3. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283–301.

    Article  PubMed  Google Scholar 

  4. Rice ME, Patel JC, Cragg SJ. Dopamine release in the basal ganglia. Neuroscience. 2011;198:112–37.

    Article  PubMed  CAS  Google Scholar 

  5. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann Neurol. 2003;53:S110–8; discussion S8–9.

    Article  PubMed  CAS  Google Scholar 

  6. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993;34:324–30.

    Article  PubMed  CAS  Google Scholar 

  7. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853–60.

    Article  PubMed  CAS  Google Scholar 

  8. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996;40:873–84.

    Article  PubMed  CAS  Google Scholar 

  9. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol. 1995;38:589–98.

    Article  PubMed  CAS  Google Scholar 

  10. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm-Supp. 1997;50:9–24.

    Article  CAS  Google Scholar 

  11. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(Suppl 7):S43–51.

    Article  PubMed  Google Scholar 

  12. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain. 1990;113 (Pt 5):1539–52.

    Article  PubMed  Google Scholar 

  13. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41:58–64.

    Article  PubMed  CAS  Google Scholar 

  14. Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med. 1998;339:1130–43.

    Article  PubMed  CAS  Google Scholar 

  15. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8.

    Article  PubMed  CAS  Google Scholar 

  16. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease A 3D [(18)F]dopa-PET study. Brain. 1999;122 (Pt 9):1637–50.

    Article  PubMed  Google Scholar 

  17. Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–30.

    Article  PubMed  CAS  Google Scholar 

  18. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson’s disease. Ann Neurol. 2003;53:206–13.

    Article  PubMed  Google Scholar 

  19. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol. 2000;47:493–503.

    Article  PubMed  CAS  Google Scholar 

  20. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain. 2011;134:3290–8.

    Article  PubMed  Google Scholar 

  21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.

    Article  PubMed  CAS  Google Scholar 

  22. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry. 2002;73:529–34.

    Article  PubMed  CAS  Google Scholar 

  23. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.

    Article  PubMed  CAS  Google Scholar 

  24. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–8.

    Article  PubMed  Google Scholar 

  25. Marek KL, Jennings DL, Seibyl JP, Parkinson Study Group. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology. 2005;64:A274-A.

    Google Scholar 

  26. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22:2210–5.

    Article  PubMed  Google Scholar 

  27. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547–55.

    Article  PubMed  CAS  Google Scholar 

  28. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson’s disease. Neurology. 1993;43:S6–16.

    PubMed  CAS  Google Scholar 

  29. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994;57:278–84.

    Article  PubMed  CAS  Google Scholar 

  30. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. European Neurology. 2008;59:258–66.

    Article  PubMed  Google Scholar 

  31. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120(Pt 12):2187–95.

    Article  PubMed  Google Scholar 

  32. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184–92.

    Article  PubMed  CAS  Google Scholar 

  33. Cummings JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1:24–36.

    Article  PubMed  CAS  Google Scholar 

  34. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol. 1996;53:538–42.

    Article  PubMed  CAS  Google Scholar 

  35. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.

    Article  PubMed  CAS  Google Scholar 

  36. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81.

    Article  PubMed  Google Scholar 

  37. McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.

    Article  PubMed  Google Scholar 

  38. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.

    Article  PubMed  CAS  Google Scholar 

  39. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology. 1993;43:552–6.

    Article  PubMed  CAS  Google Scholar 

  40. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord. 2003;18(Suppl 7):S28–33.

    Article  PubMed  Google Scholar 

  41. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord. 2002;17:518–23.

    Article  PubMed  Google Scholar 

  42. Zijlmans J, Evans A, Fontes F, et al. [123I] FP-CIT SPECT study in vascular parkinsonism and Parkinson’s disease. Mov Disord. 2007;22:1278–85.

    Article  PubMed  Google Scholar 

  43. Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688–93.

    PubMed  CAS  Google Scholar 

  44. Benaderette S, Zanotti Fregonara P, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006;21:310–7.

    Article  PubMed  Google Scholar 

  45. de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012;78:696–701.

    Article  PubMed  Google Scholar 

  46. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–82.

    Article  PubMed  CAS  Google Scholar 

  47. Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 2005;64:134–6.

    Article  PubMed  CAS  Google Scholar 

  48. Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett. 2002;323:50–4.

    Article  PubMed  CAS  Google Scholar 

  49. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–81.

    Article  PubMed  Google Scholar 

  50. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain. 2005;128:2777–85.

    Article  PubMed  Google Scholar 

  51. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology. 2008;71:1790–5.

    Article  PubMed  CAS  Google Scholar 

  52. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759–64.

    Article  PubMed  CAS  Google Scholar 

  53. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.

    Article  PubMed  CAS  Google Scholar 

  54. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608–15.

    Article  PubMed  CAS  Google Scholar 

  55. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain. 2009;132:2970–9.

    Article  PubMed  CAS  Google Scholar 

  56. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62:378–82.

    Article  PubMed  Google Scholar 

  57. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.

    Article  PubMed  CAS  Google Scholar 

  58. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. J Am Med Assoc. 2002;287:1653–61.

    Article  Google Scholar 

  59. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.

    Article  PubMed  CAS  Google Scholar 

  60. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science. 1990;247:574–7.

    Article  PubMed  CAS  Google Scholar 

  61. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589–95. (Epub 2003 Mar 31).

    Google Scholar 

  62. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997;94:2569–74.

    Article  PubMed  CAS  Google Scholar 

  63. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology. 1996;46:1430–6.

    Article  PubMed  CAS  Google Scholar 

  64. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001;49:298–303.

    Article  PubMed  CAS  Google Scholar 

  65. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain. 2004;127:2747–54. (Epub 2004 Aug 25).

    Article  PubMed  Google Scholar 

  66. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 2006;67:1612–7.

    Article  PubMed  CAS  Google Scholar 

  67. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59:852–8.

    Article  PubMed  CAS  Google Scholar 

  68. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132:1376–85.

    Article  PubMed  CAS  Google Scholar 

  69. O’Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain. 2011;134:969–78.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Imperial College Healthcare NHS Trust, Fulham Palace Road, W6 8RF, London, UK

    Yen F. Tai MRCP, PhD

  2. Centre for Neuroscience, Hammersmith Hospital Campus, Imperial College London, DuCane Road, W12 ONN, London, UK

    Nicola Pavese MD, PhD

Authors
  1. Yen F. Tai MRCP, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Pavese MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Pavese MD, PhD .

Editor information

Editors and Affiliations

  1. , Department of Neuroscience, University of California at San Diego, Gilman Dr 9500, La Jolla, 92093, California, USA

    Fatta B. Nahab

  2. , Neurorehabilitation Research Institute, Morinomiya Hospital, Morinomiya 2-1-88, Joto-ku,Osaka-shi, 536-0025, Osaka, Japan

    Noriaki Hattori

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tai, Y., Pavese, N. (2013). Dopamine Imaging in Idiopathic Parkinson Disease and Other Parkinsonisms. In: Nahab, F., Hattori, N. (eds) Neuroimaging of Movement Disorders. Current Clinical Neurology, vol 44. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-471-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-471-5_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-470-8

  • Online ISBN: 978-1-62703-471-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation